Evidence map›Paper›PMID 32503571›Full record

ArticleGlobalization and health2020

Revisiting the public health implications of the United States-Mexico- Canada agreement.

Tolulope Anthony Adekola

Open access · goldAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Globalization and health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 13 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Tolulope Anthony AdekolaSchool of Law, City University of Hong Kong, Hong Kong, Hong Kong SAR. atadekola2-c@my.cityu.edu.hk.ORCID 0000-0001-8296-9998
City University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This commentary re-examines a recent article by Labonté et al on the recent changes to two relevant provisions relating to patent rights in the final version of the United-States-Mexico-Canada Agreement (USMCA). Although the USMCA's final revised version does not add more pharmaceutical patent protection than those that already exist in the three trading partners, the agreement has done little to enhance access to generic medicines and biosimilars.

Indexed as

Biosimilar PharmaceuticalsPublic HealthCanadaCommerceInternational CooperationMexicoUnited StatesBiosimilar PharmaceuticalsBiologicsPharmaceutical patentPublic healthUSMCA

Identifiers

PMID32503571
PMCPMC7275535
OpenAlexW3034059041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.